Serum TNSALP activity correlated with bone metabolism markers, inflammation, underscoring its potential systemic role.<h4>Conclusions</h4>IAP does not seem to compensate for reduced TNSALP activity in HPP. The gene discussed is ALPL; the disease is hypophosphatasia.